

Published in final edited form as:

*Immunogenetics*. 2010 June ; 62(6): 345–356. doi:10.1007/s00251-010-0439-y.

## Haplotypes of *IL12B* promoter polymorphisms condition susceptibility to severe malaria and functional changes in cytokine levels in Thai adults

Chintana Phawong<sup>1</sup>, Collins Ouma<sup>2,3</sup>, Piyatida Tangteerawatana<sup>1,4</sup>, Jarinee Thongshoob<sup>1</sup>, Tom Were<sup>2</sup>, Yuvadee Mahakunkijcharoen<sup>1</sup>, Duangrurdee Wattanasirichaigoon<sup>5</sup>, Douglas Jay Perkins<sup>2,6</sup>, and Srisin Khusmith<sup>1</sup>

<sup>1</sup>Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand <sup>2</sup>University of New Mexico/KEMRI Laboratories of Parasitic and Viral Diseases, Centre for Global Health Research, Kisumu, Kenya <sup>3</sup>Department of Biomedical Sciences and Technology, Maseno University, Maseno, Kenya <sup>4</sup>Department of Microbiology, Faculty of Medicine, Srinakharinwirot University, Bangkok, Thailand <sup>5</sup>Division of Medical Genetics, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand <sup>6</sup>Global and Geographic Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA

### Abstract

Polymorphic variability in immune response genes, such as *IL12B*, encoding the IL-12p40 subunit is associated with susceptibility to severe malaria in African populations. Since the role of genetic variation in conditioning severe malaria in Thai adults is largely unexplored, the functional association between *IL12B* polymorphisms [i.e., *IL12B*pro (rs17860508), and *IL12B* 3' UTR T/G (rs3212227)], severe malaria, and cytokine production was examined in patients with *Plasmodium falciparum* infections (n=355) recruited from malaria endemic areas along the Thai-Myanmar border in northwest Thailand. Circulating IL-12p40 ( $p=0.049$ ) and IFN- $\gamma$  ( $p=0.051$ ) were elevated in patients with severe malaria, while only IL-12p40 was significantly higher in severe malaria patients with hyperparasitaemia ( $p=0.046$ ). Carriage of the *IL12B*pro1.1 genotype was associated with enhanced severity of malaria (OR, 2.34; 95% CI, 0.94–5.81;  $p=0.066$ ) and hyperparasitaemia (OR, 3.42; 95% CI, 1.17–9.87;  $p=0.025$ ) relative to the *IL12B*pro2.2 genotype (wild type). Individuals with the *IL12B*pro1.1 genotype also had the lowest IL-12p40 ( $p=0.002$ ) and the highest IFN- $\gamma$  ( $p=0.004$ ) levels. Construction of haplotypes revealed that carriage of the *IL12B*pro-2/3' UTR-T haplotype was associated with protection against severe malaria (OR, 0.51; 95% CI, 0.29–0.90;  $p=0.020$ ) and reduced circulating IFN- $\gamma$  ( $p=0.06$ ). Thus, genotypic and

**Please address any correspondences to:** Dr. Srisin Khusmith, Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Road, Bangkok 10400, Thailand. Tel: 66-2-3549100-13 ext 1594; Fax: 66-2-6435583. tmskm@mahidol.ac.th, or, Dr. Douglas J. Perkins, Director, Global and Geographic Medicine, Division of Infectious Diseases, University of New Mexico School of Medicine, MSC10-5550, 1 University of New Mexico, Albuquerque, NM 87131-0001, Tel: 505-272-6867; Fax: 505-272-8441., dperkins@salud.unm.edu.

There is no conflict of interest for any of the authors of the manuscript due to commercial or other affiliations.

### Authors' contributions

SK, DJP and CP designed the study. CP collected blood samples, genotyped the *IL12B*pro and *IL12B* 3' UTR polymorphisms, participated in data analysis, and writing of the manuscript. CO assisted in genotyping of *IL12B*pro (rs17860508) polymorphisms, data analysis, and writing of the manuscript. PT collected blood samples and determined the circulating IFN- $\gamma$  levels. JT determined circulating IL-12p40 levels. TW assisted in genotyping of *IL12B* 3' UTR polymorphisms and data analysis. DW and YM assisted in data analysis. SK and DJP financed the study, performed data analyses and co-wrote the manuscript. All authors have read and approved the final version of the manuscript.

haplotypic variation at *IL12B*pro and *IL12B* 3' UTR in this population influences susceptibility to severe malaria and functional changes in circulating IL-12p40 and IFN- $\gamma$  levels. Results presented here suggest that protection against severe malaria in Thai adults is associated with genotypic variants that condition enhanced IL-12p40 and reduced IFN- $\gamma$  levels.

## Keywords

*IL12B*; *P. falciparum*; severe malaria; single nucleotide polymorphism; haplotype

## Introduction

Infection with *P. falciparum* displays a wide spectrum of disease manifestations ranging from asymptomatic presentation to severe disease. The host immune response to malaria is coordinated by the release of pro- and anti-inflammatory cytokines (Kurtzhals et al. 1999; Luty et al. 2000; Othoro et al. 1999; Perkins et al. 2000; Prakash et al. 2006). Depending on the temporal expression and magnitude of production, pro-inflammatory (type-1) cytokines, such as interleukin (IL)-12, and interferon (IFN)- $\gamma$ , promote both protective and pathogenic responses in malaria (McDevitt et al. 2004). IL-12 is produced primarily by antigen presenting cells (Ing et al. 2006) and promotes IFN- $\gamma$  release from cells of the innate immune system, including natural killer (NK) cells (Artavanis-Tsakonas and Riley 2002; Hansen et al. 2007), NK-T cells (Schmiege et al. 2003), and  $\gamma\delta$  T cells (D'Ombrain et al. 2007). IL-12 is also important in adaptive immunity through its ability to augment IFN- $\gamma$  production from CD4<sup>+</sup> T cells (Stephens and Langhorne 2006) and CD8<sup>+</sup> T cells (Schmidt et al. 2009). As such, IL-12-promoted release of IFN- $\gamma$  is a primary mechanism for limiting intracellular pathogen growth (Chehimi and Trinchieri 1994).

IL-12 plays an important protective role against malaria in murine (Mohan and Stevenson 1998b; Sam and Stevenson 1999) and human systems (Boutlis et al. 2003; Keller et al. 2006; Perkins et al. 2000; Prakash et al. 2006; Wroczynska et al. 2005). Reduced circulating levels of IL-12 are associated with enhanced malaria pathogenesis in African children (Luty et al. 2000; Perkins et al. 2000) and non-immune adults (Wroczynska et al. 2005), while elevated plasma concentrations are associated with increased severity of malaria in Asian adults (Gosi et al. 1999; Prakash et al. 2006).

In addition, IFN- $\gamma$  is an essential mediator of protective immunity against erythrocytic malaria (Favre et al. 1997; Stevenson et al. 1995). Early release of IL-12, IFN- $\gamma$ , and TNF- $\alpha$  in murine models of malaria promotes resistance to infection (De Souza et al. 1997; Favre et al. 1997; Mitchell et al. 2005; Shear et al. 1989; Stevenson et al. 1995). Results from studies in humans also show that enhanced cellular IFN- $\gamma$  responses are associated with protective immunity against clinical malaria (Iriemenam et al. 2009; Luty et al. 1999; Migot-Nabias et al. 1999; Robinson et al. 2009). In contrast, other investigations have found that elevated circulating levels of IFN- $\gamma$  are associated with increased pathophysiology of falciparum malaria (Day et al. 1999; Prakash et al. 2006).

Susceptibility to malaria infections and the clinical course of disease once an individual becomes infected are influenced by host genetic variation (Verra et al. 2008; Verra et al. 2009; Weatherall 2008). Association-studies in malaria have shown that variation in both innate and adaptive immune pathways condition disease susceptibility and outcomes (Kwiatkowski 2005). Since IL-12 is important for mediating malaria disease outcomes, the current study investigated the role of genetic variation in *IL12B* in conditioning susceptibility to severe malaria in Thai adults infected with *P. falciparum*. IL-12 is a heterodimer composed of IL-12p35 and IL-12p40 subunits, encoded by *IL12A* and *IL12B*

genes located on chromosomes 3p12–q13.2 and 5q31–33, respectively (Sieburth et al. 1992). A number of single nucleotide polymorphisms (SNPs) have been identified in the *IL12B* gene, including an *IL12B* promoter polymorphism (*IL12B*pro, a bi-allelic promoter polymorphism located at –2703 bp from the transcription initiation site, rs17860508) and a TaqI polymorphism (a T to G transition at 1188) in the *IL12B* 3' untranslated region (referred to as *IL12B* 3' UTR from hence forth, rs321227) (Huang et al. 2000). These variants have been shown to be important for conditioning susceptibility to a number of infectious (Marquet et al. 2008; Morahan et al. 2002; Mueller et al. 2004; Tso et al. 2004) and inflammatory diseases (Cargill et al. 2007; Zwiens et al. 2004). Although the relationship between genetic variability in *IL12B* and susceptibility to severe malaria has shown mixed results (Barbier et al. 2008; Marquet et al. 2008; Morahan et al. 2002), homozygosity for the CTCTAA (*IL12B*pro1) allele of the *IL12B* promoter variant is associated with increased mortality in Tanzanian children with cerebral malaria, but not Kenyan children with severe malaria (Morahan et al. 2002). Variability in *IL12B* was further associated with *P. falciparum* parasitaemia in Burkina Faso (Flori et al. 2003; Rihet et al. 1999), however, subsequent familial-based studies failed to show a significant correlation between *IL12B*pro and a polymorphism in the 3' untranslated region of *IL12B* (*IL12B* 3' UTR) and hyperparasitaemia (Barbier et al. 2008).

The aim of the present study was to determine the role of *IL12B*pro and *IL12B* 3' UTR variants in conditioning susceptibility to severe malaria and functional changes in IL-12 and IFN- $\gamma$  levels in Thai adults with falciparum malaria. The primary hypothesis of the study is that haplotypes of *IL12B* form functional blocks that mediate susceptibility to severe malaria by altering the levels of two critical cytokines that regulate innate and adaptive immune responses: IL-12 and IFN- $\gamma$ . Determining the role of genetic variability in conditioning susceptibility to severe malaria in Thai adults, particularly in terms of haplotypic blocks, is significant since the genes and gene pathways that mediate disease outcomes are largely unexplored in this population. Results presented here demonstrate that genotypes/haplotypes of *IL12B*pro and *IL12B* 3' UTR are associated with differing susceptibilities to severe malaria and altered circulating levels of IL-12 and IFN- $\gamma$ .

## Methods and Materials

### Study subjects

Patients with falciparum malaria (n=355; age 18 to 67 yrs., mean  $\pm$  SD=28.3 $\pm$ 10.5) admitted to the Hospital for Tropical Diseases, Faculty of Tropical Medicine, Mahidol University, Bangkok were enrolled in an unmatched case-control study. The patients included those with severe malaria (n=103, cases) and those with uncomplicated malaria (n=252, controls) who had been living along the Thai-Myanmar border in the northwest of Thailand where malaria is endemic. These areas are considered to be of low malaria endemicity with two peak seasonal transmissions in May–July and November–January (Luxemburger et al. 1997; Nacher et al. 2001). Incidence rates of malaria were 2–6 cases/1000 population in 2001 (Socheat et al. 2003). In this region, adults are most at risk for the complications of severe malaria including hyperparasitaemia, jaundice, renal dysfunction and cerebral malaria, with severe malarial anaemia occurring only rarely. All patients with non-falciparum malaria infections, mixed *Plasmodium* infections, and the signs and symptoms of AIDS defining illness and/or meningitis were excluded from the study.

All patients were positive for *P. falciparum* infection by microscopic examination of thin and thick blood smears stained with Giemsa. Severe and uncomplicated malaria were defined according to World Health Organization criteria (WHO 2000). Cerebral malaria was defined as an unarousable coma with positive asexual forms of *P. falciparum* in peripheral blood. Severe malaria, in the absence of cerebral malaria, was defined as individuals with

one or more of the following signs: hyperparasitaemia (>250,000 parasites/ $\mu$ L); hypoglycaemia (glucose <2.2 mmol/L); severe anaemia (haematocrit <20% or haemoglobin <7.0 g/dL) or increased serum levels of creatinine >3.0 mg/dL. Study participants with positive *P. falciparum* blood films who lacked these signs of severe malaria were categorized as uncomplicated malaria (controls). Patients with severe malaria were further stratified into hyperparasitaemia ( $\geq$ 250,000 parasites/ $\mu$ L) and non-hyperparasitaemia (<250,000 parasites/ $\mu$ L). The study was approved by the Ethical Committee of the Faculty of Tropical Medicine, Mahidol University, Bangkok, with informed written consent obtained from all study participants.

### Laboratory measures

Venipuncture blood (3–5 mL) was collected aseptically in EDTA-containing tubes prior to any treatment interventions. Plasma and packed cells were separated by centrifugation and stored at  $-20^{\circ}\text{C}$  until use. Laboratory measures included parasite density determination, complete blood count (CBC) and clinical biochemistry tests. Parasite densities were determined and the number of parasites/1000 erythrocytes (in thin blood films) or parasites/200 leukocytes (in thick films) were calculated and expressed as *P. falciparum* parasites/ $\mu$ L of blood.

### DNA extraction and whole genome amplification

Genomic DNA was extracted using a FlexiGene DNA extraction kit (QIAGEN, Valencia, CA). Prior to genotyping, whole genome amplification was performed by isothermal strand displacement using GenomiPhi V2 DNA Amplification kit (GE Healthcare, Piscataway, NJ).

### Genotyping

*IL12B* 3' UTR (rs3212227) polymorphisms were genotyped using TaqMan<sup>®</sup> 5' Allelic Discrimination Pre-Designed Assays (Applied Biosystems, USA). *IL12B*pro (rs17860508) genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) as described previously (Khoo et al. 2004) with some minor modifications. Briefly, the primers were: 5'-TACAGCCTGTCTCCGAG AGAA-3' and 5'-GAGGAAGTGGTTCTCGTACTTTAGC-3'. The PCR reaction was performed in a 25  $\mu$ L reaction mixture containing 100 ng DNA, 2.5 mmol/L MgCl<sub>2</sub>, 200 mmol/L dNTPs, 12.5 ng and 1 unit of Taq DNA polymerase (Promega, Madison, WI) in buffer (10 mmol/L Tris-HCl, pH 9.0 and 50 mmol/L KCl). Underlined bases (indicated in the forward and reverse primers) were inserted to create an *Alu* I site in allele 1 (CTCTAA) or in allele 2 (GC). PCR conditions consisted of an initial 3 min. denaturation at 95  $^{\circ}\text{C}$ , followed by 40 cycles of denaturation at 95  $^{\circ}\text{C}$  for 30 sec., annealing at 62  $^{\circ}\text{C}$  for 30 sec. and extension at 72  $^{\circ}\text{C}$  for 45 sec. with a final extension at 72  $^{\circ}\text{C}$  for 7 min. PCR products (15  $\mu$ L) were further digested in a 20  $\mu$ L reaction volume containing 1.5 units of *Alu*I (New England Biolabs, USA) at 37  $^{\circ}\text{C}$  for 14 hrs. Digested products were separated on 4% high resolution agarose gel (Agarose SFR, Amresco, Solon, OH) containing ethidium bromide and visualized under UV illumination.

### Determination of circulating IL-12p40 and IFN- $\gamma$ levels

Plasma IL-12p40 levels were determined by enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions (BD Biosciences Pharmingen, San Diego, CA). Circulating levels of IFN- $\gamma$  were determined by ELISA (R&D systems, Minneapolis, MN) as previously described (Tangteerawatana et al. 2007). Optical densities were measured at 405 nm wavelength and cytokine concentrations were calculated from the standard curve

using recombinant human IL-12 p40 and IFN- $\gamma$ , respectively. Lower limits of detection for IL-12p40 and IFN- $\gamma$  were 10 pg/mL and 25 pg/mL, respectively.

### Statistical analyses

Statistical analyses were performed using Minitab<sup>®</sup> 15 Statistical Software (Minitab Inc., State college, PA) and SPSS (Version 15.0, SPSS Inc., Chicago, IL). Deviation from Hardy-Weinberg equilibrium was determined using web-based calculations ([http://www.kursus.kvl.dk/shares/vetgen\\_Popgen/genetic/appleys/kitest.htm](http://www.kursus.kvl.dk/shares/vetgen_Popgen/genetic/appleys/kitest.htm)). Chi-square ( $\chi^2$ ) analyses were used to compare proportions. Students's t-test was used to compare demographic and clinical characteristics in uncomplicated versus severe malaria. Across group comparisons were determined by Kruskal-Wallis tests, and were significant, Mann-Whitney *U* tests were used for post-hoc comparisons. *IL12B* haplotypes (*IL12B*pro and *IL12B* 3' UTR T/G) were constructed using HPlus software (Version 2.5). The association between individual polymorphisms (and haplotypes) and malaria clinical outcomes were determined by multivariate logistic regression analysis, controlling for the confounding effects of age and gender. Statistical significance was defined as  $p \leq 0.05$ .

## Results

### Demographic, clinical and laboratory characteristics of the study subjects

The demographic, clinical and laboratory characteristics of the study subjects are shown in Table 1. No significant differences were observed in the distribution of age ( $p=0.082$ ) between the severe (SM) and the uncomplicated malaria (UM) groups. Gender differed significantly between the two groups ( $p=0.002$ ). Peripheral parasitaemia was also significantly different between the groups ( $p<0.001$ ) with the highest parasitaemia present in the severe malaria group. Although haemoglobin (Hb) concentrations were not significantly lower in the SM group ( $p=0.091$ ), the number of red blood cells (RBCs) was significantly reduced ( $p=0.007$ ) in these patients. The white blood cell (WBC) count was elevated in the SM group ( $p<0.001$ ), while lymphocyte counts and platelets were significantly lower ( $p<0.001$  and  $p<0.001$ , respectively). Total bilirubin and creatinine concentrations were significantly higher in patients with severe malaria ( $p<0.001$  and  $p=0.029$ , respectively).

### Circulating levels of IL-12p40 and IFN- $\gamma$ in malaria-infected patients

Prior to determining the influence of *IL12B* genotypes/haplotypes on susceptibility to severe malaria and functional changes in cytokine production, circulating levels of IL-12p40 and IFN- $\gamma$  were determined in the UM and SM groups, and in patients with severe malaria with and without hyperparasitaemia. As shown in Table 2, patients with severe malaria had significantly higher circulating IL-12p40 levels [median (IQR): 95.1 (27.6–133.1)] than those with uncomplicated malaria [median (IQR): 27.0 (10.0–98.8),  $p=0.049$ ]. In addition, circulating IFN- $\gamma$  levels were also higher in patients with severe malaria [median (IQR): 387.0 (144.2–632.0)] compared to the uncomplicated malaria group [median (IQR): 283.5 (118.5–473.5),  $p=0.051$ , Table 2].

Analysis of IL-12 and IFN- $\gamma$  in patients with severe malaria, stratified according to hyperparasitaemia, demonstrated that individuals with hyperparasitaemia had significantly higher circulating IL-12p40 levels [median (IQR): 121.9 (43.3–163.3)] than those with non-hyperparasitaemia [median (IQR): 35.1 (12.5–103.9)],  $p=0.046$ , Table 2]. However, circulating IFN- $\gamma$  levels were not significantly different in severe malaria patients with and without hyperparasitaemia (Table 2).



### Distribution of *IL12B*pro and *IL12B* 3' UTR genotypic frequencies

The distribution of genotypes for *IL12B*pro and *IL12B* 3' UTR are presented in Table 3. The distribution of the *IL12B*pro1.1 and *IL12B* 3' UTR GG genotypes was significantly different between the UM and the SM groups ( $p=0.017$  and  $p=0.021$ , respectively). None of the other genotypes showed any significant differences in frequency between the UM and SM groups.

Further investigation of the *IL12B*pro polymorphism revealed significant departure from Hardy-Weinberg equilibrium (HWE) in the UM ( $\chi^2=63.28$ ,  $p<0.001$ ) and SM ( $\chi^2=16.41$ ,  $p<0.001$ ) groups, respectively. However, the *IL12B* 3' UTR polymorphism failed to display significant departure from HWE in both the UM ( $\chi^2=1.28$ ;  $p>0.05$ ) and SM ( $\chi^2=2.68$ ;  $p>0.05$ ) groups, respectively.

### Association between *IL12B* polymorphisms and susceptibility to severe malaria and hyperparasitaemia

Multivariate logistic regression analyses were used to determine the association between variability in each of the two *IL12B* polymorphisms and severe malaria, controlling for the confounding effects of age and gender. In addition, since hyperparasitaemia is a prominent feature of severe malaria in Thailand, multivariate modelling (controlling for identical co-factors) was used to examine the relationship between variation in *IL12B* genes and hyperparasitaemia in patients with severe malaria. Presence of the *IL12B*pro1.1 genotype was associated with increased susceptibility to severe malaria (OR, 2.34; 95% CI, 0.94–5.81,  $p=0.066$ ) and hyperparasitaemia (OR, 3.42; 95% CI, 1.17–9.97,  $p=0.025$ , Table 4).

In addition, heterozygous (TG) individuals at the *IL12B* 3' UTR locus were 39% less likely to develop severe malaria (OR, 0.61; 95% CI, 0.33–1.00,  $p=0.096$ ), while homozygous polymorphic individuals (GG) were 30% less likely to develop severe malaria (OR, 0.60; 95% CI, 0.36–1.39,  $p=0.311$ , Table 4). Variation at *IL12B* 3' UTR did not show any prominent relationships with hyperparasitaemia.

### Association between *IL12B* haplotypes and susceptibility to severe malaria and hyperparasitaemia

Following analyses of the individual variants, haplotypes were constructed using HPlus software. The following haplotypic distributions were generated: 68.9% (184/267) *IL12B*pro-2/3' UTR-T; 26.2% (70/267) *IL12B*pro-2/3' UTR-G; 12.7% (34/267) *IL12B*pro-1/3' UTR-T; and 68.9% (184/267) *IL12B*pro-1/3' UTR-G. Multivariate logistic regression analyses, controlling for the confounding effects of age and gender, were used to determine the association of *IL12B* haplotypes with severe malaria and hyperparasitaemia. The model was constructed such that those *with* versus those *without* presence of the haplotype were compared. The *IL12B*pro-2/3' UTR-T haplotype was associated with significant protection against severe malaria (OR, 0.51; 95% CI, 0.29–0.90,  $p=0.020$ ) and non-significant protection against hyperparasitaemia (OR, 0.57; 95% CI, 0.28–1.18,  $p=0.132$ , Table 5). Additional analyses failed to show any significant haplotypic associations with susceptibility to either severe malaria or hyperparasitaemia for *IL12B*pro-1/3' UTR-G, *IL12B*pro-2/3' UTR-G, and *IL12B*pro-1/3' UTR-T (Table 5).

### Functional relationship between the *IL12B* polymorphisms and circulating levels of IL-12p40 and IFN- $\gamma$

Since variation in *IL12B* may influence IL-12p40 and IFN- $\gamma$  production, circulating levels of IL-12p40 and IFN- $\gamma$  were compared across the UM and SM groups stratified according to genotype for their respective polymorphisms (Table 6). There was a significance difference in IL-12p40 levels across the UM group ( $p=0.002$ ), but not in individuals with SM ( $p=0.919$ ). Post-hoc testing of the UM group revealed that carriage of the *IL12B*pro1.2

genotype was associated with significantly higher IL-12p40 levels [median (IQR): 75.4 (13.5–112.5)] compared to the *IL12B*pro1.1 genotype [median (IQR): 10.0 (10.0–10.0),  $p=0.002$ ] and the *IL12B*pro2.2 genotype [median (IQR): 20.0 (10.0–69.3),  $p=0.040$ ]. In addition, patients with the *IL12B*pro2.2 genotype also had higher IL-12p40 levels than those with *IL12B*pro1.1 genotype ( $p=0.002$ ).

Stratification according to *IL12B*pro genotypes showed that IFN- $\gamma$  levels were also significantly different across the UM group ( $p=0.004$ ), but not across the SM group ( $p=0.508$ ). Post-hoc analyses of the UM group revealed that carriage of the *IL12B*pro1.1 genotype [median (IQR): 438.5 (227.7–585.2)] was associated with significantly higher IFN- $\gamma$  levels compared to the *IL12B*pro2.2 genotype [median (IQR): 140.0 (43.0–314.0),  $p=0.002$ ]. In addition, individuals with the *IL12B*pro1.2 genotype [median (IQR): 338.5 (125.5–522.2)] also had significantly higher IFN- $\gamma$  levels than those with the *IL12B*pro2.2 genotype ( $p=0.004$ ).

Comparison of IL-12p40 and IFN- $\gamma$  levels across the UM and SM groups stratified according to the *IL12B* 3' UTR polymorphisms did not reveal any significant differences.

### Functional relationship between *IL12B* haplotypes and circulating IL-12 and IFN- $\gamma$ levels

To determine if haplotypes were associated with functional changes in IL-12 and IFN- $\gamma$  production, circulating concentrations of these mediators were compared across the haplotypic groups. Although differences in IFN- $\gamma$  levels approached significance between individuals with the *IL12B*pro-2/3' UTR-T haplotype [median (IQR); 267.5 (117.5–527.0)] relative to those with the non-*IL12B*pro-2/3' UTR-T haplotype [median (IQR); 387.0 (164.0–597.0),  $p=0.06$ ], none of the other haplotypes showed any functional association with circulating IL-12 and IFN- $\gamma$  levels (Table 6).

## Discussion

Although the literature is replete with studies investigating genetic susceptibility to severe malaria in African populations, much less information is available about how variation in immune response genes condition severe disease outcomes in Southeast Asia. As such, we utilized a candidate gene approach to focus on the role of IL-12 in shaping severe malaria outcomes in Thai adults with falciparum malaria. IL-12 was selected for investigation since this type I cytokine plays a critical role in protection against malaria in both animal models (Mohan and Stevenson 1998a; Sam and Stevenson 1999) and in humans (Boutlis et al. 2003; Gosi et al. 1999; Keller et al. 2006; Luty et al. 2000; Perkins et al. 2000; Wroczynska et al. 2005). We hypothesized that exploration of variation in two previously identified polymorphisms in *IL12B* (i.e., *IL12B*pro and *IL12B* 3'UTR) may provide insight into the role of IL-12 in mediating susceptibility to severe malaria and another primary feature of severe falciparum malaria in Thai adults: hyperparasitaemia. The cross-sectional study design utilized for the current investigation included only patients with *P. falciparum* parasitaemia so that we could explore the role of IL-12 in mediating severe disease outcomes once an individual acquires malaria.

Prior to determining the effect of *IL12B* genotypes and haplotypes on conditioning disease outcomes and functional changes in IL-12p40 and IFN- $\gamma$  production, we examined these cytokines in parasitized individuals stratified according to uncomplicated and severe malaria, and in severe malaria patients with and without hyperparasitaemia. Circulating levels of IL-12p40 and IFN- $\gamma$  were highest in patients with severe malaria and hyperparasitaemia, respectively. The patterns of cytokine expression observed here are both similar and different from a number of previous studies conducted in populations with differing ages and levels of malaria endemicity. For example, results presented here in the

largely less immune adult population to malaria most closely resemble studies in non-immune adults undergoing experimental infection with *P. falciparum* in which there was an early release of plasma IL-12p40 and IFN- $\gamma$  (Hermsen et al. 2003). Our results differ somewhat from previous studies in Cameroon in which plasma levels of IL-12p40 and IL-12p70 were not significantly elevated in children with severe malaria, while circulating concentrations of IFN- $\gamma$  were significantly higher in this group (Hermsen et al. 2003). In addition, results presented here differ from investigations in Gabon and Kenya demonstrating that severe childhood malaria is characterized by suppression of circulating IL-12 p40/p70 levels (Keller et al. 2006; Luty et al. 2000; Perkins et al. 2000). An additional explanation for the heterogeneity in IL-12p40/p70 and IFN- $\gamma$  responses in the differing populations may be, at least in part, due to host genetic factors (Artavanis-Tsakonas and Riley 2002; D'Ombraïn et al. 2007; D'Ombraïn et al. 2008; Mueller et al. 2004; Peng et al. 2006; Shimokawa et al. 2009). Genotyping of the overall population in the study revealed frequencies for the *IL12B*pro polymorphism at 8.8% (*IL12B*pro1.1), 72.8% (*IL12B*pro1.2) and 18.4% (*IL12B*pro2.2), while frequencies for the *IL12B* 3' UTR polymorphism were 26.2% (TT), 44.7% (TG), 29.1% (GG). Among patients with severe malaria there were significantly elevated frequencies of *IL12B*pro1.1 and *IL12B* 3' UTR-GG compared to the uncomplicated malaria group, while none of the other distributions significantly differed. Frequencies of the *IL12B*pro polymorphism in the Thai population investigated here differ from those observed in Chinese (Tso et al. 2004) and Spanish (Orozco et al. 2005) populations. Distributions of the *IL12B* 3' UTR polymorphism were comparable to those reported previously in Thai (Nair et al. 2000) and Japanese (Yang et al. 2006) populations, but different from observations in Caucasian Americans and African Americans (Ma et al. 2003).

Multivariate analyses, controlling for the confounding effects of age and gender, revealed that carriage of the *IL12B*pro1.1 genotype was associated with a non-significant increase in the risk of severe malaria and a significant increase in susceptibility to hyperparasitaemia. However, variation at the *IL12B* 3' UTR was not associated with susceptibility to either severe malaria or hyperparasitaemia. Since haplotypes can identify important associations with disease outcomes that may not be reflected by analysis of individual loci, we performed haplotypic analyses. Construction of haplotypes for the two *IL12B* polymorphisms revealed that carriage of the *IL12B*pro-2/3' UTR-T haplotype was associated with a 49% reduction in severe malaria ( $p=0.020$ ) and a 43% reduction in hyperparasitaemia ( $p=0.132$ ). Additional haplotypic analyses did not reveal any significant associations with severe malaria or hyperparasitaemia. Although not statistically significant, it is important to note that individuals with the *IL12B*pro-1/3' UTR-T haplotype had a 115% increase in susceptibility to hyperparasitaemia relative to those without the haplotype. The lack of statistical significance for this haplotype likely reflects reduced sample size issues in the current study that may deserve closer inspection in a larger cohort.

Recent reports illustrate that the *IL12B*pro and *IL12B* 3' UTR polymorphisms affect IL-12 gene expression (Shimokawa et al. 2009) and IL-12 production *in vitro* (Muller-Berghaus et al. 2004; Peng et al. 2006; Seegers et al. 2002). Results presented here demonstrate that carriage of the heterozygous (i.e., *IL12B*pro1.2) genotype was associated with significantly higher IL-12p40 levels in patients with uncomplicated malaria. In individuals with severe malaria, carriage of the *IL12B*pro2 allele was associated with the highest levels of IL-12p40, suggesting that this allele may functionally influence increased IL-12 production. These results are consistent with the fact that the *IL12B*pro2 allele appears to influence IL-12 production by altering Sp1-mediated transcription activity (Shimokawa et al. 2009). These results also parallel the studies in Papua New Guineans and Africans showing that the *IL12B*pro1.1 genotype was associated with reduced circulating levels of IL-12p40 and elevated parasitaemia (Boutlis et al. 2003). In contrast to IL-12, IFN- $\gamma$  levels were highest in



individuals with the *IL12B*pro1.1 polymorphism in both uncomplicated and severe malaria. Thus, although enhanced IL-12 production is typically associated with elevated IFN- $\gamma$  levels, the results presented here illustrate that this relationship is not present in Thai adults with malaria, and that this relationship is conditioned by variation in the *IL12B* promoter. Analysis of cytokine production stratified according to haplotypes revealed that the *IL12B*pro-2/3' UTR-T that conditioned decreased susceptibility to severe malaria was also associated with reduced IFN- $\gamma$  levels. These results are consistent with our finding that individuals with severe malaria have the highest levels of circulating IFN- $\gamma$ , suggesting that over-expression of IFN- $\gamma$  in this population may be important for enhancing the development of severe malaria.

In conclusion, results presented here in Thai adults with falciparum malaria illustrate that elevated expression of IL-12 and IFN- $\gamma$  are associated with severe disease, and a primary clinical feature of severe disease (i.e., hyperparasitaemia) in this population. This study further illustrates that haplotypes of the *IL12B*pro and 3' UTR polymorphisms, namely the *IL12B*pro-2/3' UTR-T, is associated with decreased susceptibility to severe malaria and reduced circulating levels of IFN- $\gamma$ . As such, it appears that one primary effect of variation in the *IL12B* promoter on conditioning disease severity in this population may be, at least in part, mediated through IFN- $\gamma$ . Future studies aimed at examining additional variation in *IL12B*, as well as *IFN- $\gamma$*  genes, may provide important insight into the complex genetic pathways that condition susceptibility to severe malaria in Thai adults.

## Acknowledgments

We wish to thank the late Professor Sornchai Looareesuwan, Department of Clinical Tropical Medicine and Hospital for Tropical Diseases, Mahidol University for providing blood samples and clinical data. We also thank his staff for assistance in blood collection and slide reading. We thank the patients for their kind participation in the study.

**Financial support:** This study was supported by the Royal Golden Jubilee Ph.D. Program (PHD/0197/2549) of the Thailand Research Fund (CP and SK), the Commission on Higher Education of Thailand (CP), the National Institutes of Health [A151305-06 (DJP) and TW05884-06 (DJP)] and the Faculty of Tropical Medicine, Mahidol University.

## List of abbreviations used

<b>SNP</b>	single nucleotide polymorphism
<b>IL-12</b>	Interleukin-12
<b>IL-12p40</b>	40-kDa subunit of IL-12
<b>IFN-<math>\gamma</math></b>	Interferon gamma
<b><i>IL12B</i></b>	gene encoding 40-kDa subunit of IL-12
<b><i>IL12B</i> 3' UTR</b>	A→C SNP located in the 3' untranslated region (UTR) at position 1188 of the <i>IL12B</i> gene
<b><i>IL12B</i>pro</b>	a compound polymorphism involving a GC/TT transition combined with an AGAG micro-insertion within the promoter region of the <i>IL12B</i> pro

## References

Artavanis-Tsakonas K, Riley EM. Innate immune response to malaria: rapid induction of IFN-gamma from human NK cells by live *Plasmodium falciparum*-infected erythrocytes. *J Immunol* 2002;169:2956–2963. [PubMed: 12218109]

- Barbier M, Atkinson A, Fumoux F, Rihet P. *IL12B* polymorphisms are linked but not associated with *Plasmodium falciparum* parasitaemia: a familial study in Burkina Faso. *Genes Immun* 2008;9:405–411. [PubMed: 18449199]
- Boutlis CS, Lagog M, Chaisavaneeayakorn S, Misukonis MA, Bockarie MJ, Mgone CS, Wang Z, Morahan G, Weinberg JB, Udhayakumar V, Anstey NM. Plasma interleukin-12 in malaria-tolerant Papua New Guineans: inverse correlation with *Plasmodium falciparum* parasitaemia and peripheral blood mononuclear cell nitric oxide synthase activity. *Infect Immun* 2003;71:6354–6357. [PubMed: 14573655]
- Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, Matsunami N, Ardlie KG, Civello D, Catanese JJ, Leong DU, Panko JM, McAllister LB, Hansen CB, Papenfuss J, Prescott SM, White TJ, Leppert MF, Krueger GG, Begovich AB. A large-scale genetic association study confirms *IL12B* and leads to the identification of IL23R as psoriasis-risk genes. *Am J Hum Genet* 2007;80:273–290. [PubMed: 17236132]
- Cehimi J, Trinchieri G. Interleukin-12: a bridge between innate resistance and adaptive immunity with a role in infection and acquired immunodeficiency. *J Clin Immunol* 1994;14:149–161. [PubMed: 7929692]
- D'Ombra MC, Hansen DS, Simpson KM, Schofield L. Gammadelta-T cells expressing NK receptors predominate over NK cells and conventional T cells in the innate IFN-gamma response to *Plasmodium falciparum* malaria. *Eur J Immunol* 2007;37:1864–1873. [PubMed: 17557374]
- D'Ombra MC, Robinson LJ, Stanicic DI, Taraika J, Bernard N, Michon P, Mueller I, Schofield L. Association of early interferon-gamma production with immunity to clinical malaria: a longitudinal study among Papua New Guinean children. *Clin Infect Dis* 2008;47:1380–1387. [PubMed: 18947328]
- Day NP, Hien TT, Schollaardt T, Loc PP, Chuong LV, Chau TT, Mai NT, Phu NH, Sinh DX, White NJ, Ho M. The prognostic and pathophysiologic role of pro- and anti-inflammatory cytokines in severe malaria. *J Infect Dis* 1999;180:1288–1297. [PubMed: 10479160]
- De Souza JB, Williamson KH, Otani T, Playfair JH. Early gamma interferon responses in lethal and nonlethal murine blood-stage malaria. *Infect Immun* 1997;65:1593–1598. [PubMed: 9125535]
- Favre N, Ryffel B, Bordmann G, Rudin W. The course of *Plasmodium chabaudi chabaudi* infections in interferon-gamma receptor deficient mice. *Parasite Immunol* 1997;19:375–383. [PubMed: 9292896]
- Flori L, Kumulungui B, Aucan C, Esnault C, Traore AS, Fumoux F, Rihet P. Linkage and association between *Plasmodium falciparum* blood infection levels and chromosome 5q31–q33. *Genes Immun* 2003;4:265–268. [PubMed: 12761562]
- Gosi P, Khusmith S, Looareesuwan S, Sitachamroom U, Glanarongran R, Buchachart K, Walsh DS. Complicated malaria is associated with differential elevations in serum levels of interleukins 10, 12, and 15. *Southeast Asian J Trop Med Public Health* 1999;30:412–417. [PubMed: 10774644]
- Hansen DS, Bernard NJ, Nie CQ, Schofield L. NK cells stimulate recruitment of CXCR3+ T cells to the brain during *Plasmodium berghei*-mediated cerebral malaria. *J Immunol* 2007;178:5779–5788. [PubMed: 17442962]
- Hermesen CC, Konijnenberg Y, Mulder L, Loe C, van Deuren M, van der Meer JW, van Mierlo GJ, Eling WM, Hack CE, Sauerwein RW. Circulating concentrations of soluble granzyme A and B increase during natural and experimental *Plasmodium falciparum* infections. *Clin Exp Immunol* 2003;132:467–472. [PubMed: 12780694]
- Huang D, Cancilla MR, Morahan G. Complete primary structure, chromosomal localisation, and definition of polymorphisms of the gene encoding the human interleukin-12 p40 subunit. *Genes Immun* 2000;1:515–520. [PubMed: 11197695]
- Ing R, Segura M, Thawani N, Tam M, Stevenson MM. Interaction of mouse dendritic cells and malaria-infected erythrocytes: uptake, maturation, and antigen presentation. *J Immunol* 2006;176:441–450. [PubMed: 16365437]
- Iriemenam NC, Okafor CM, Balogun HA, Ayede I, Omosun Y, Persson JO, Hagstedt M, Anumudu CI, Nwuba RI, Troye-Blomberg M, Berzins K. Cytokine profiles and antibody responses to *Plasmodium falciparum* malaria infection in individuals living in Ibadan, southwest Nigeria. *Afr Health Sci* 2009;9:66–74. [PubMed: 19652739]

- Keller CC, Yamo O, Ouma C, Ong'echa JM, Ounah D, Hittner JB, Vulule JM, Perkins DJ. Acquisition of haemozoin by monocytes down-regulates interleukin-12 p40 (IL-12p40) transcripts and circulating IL-12p70 through an IL-10-dependent mechanism: *in vivo* and *in vitro* findings in severe malarial anaemia. *Infect Immun* 2006;74:5249–5260. [PubMed: 16926419]
- Khoo SK, Hayden CM, Roberts M, Horak E, de Klerk N, Zhang G, Robertson CF, Goldblatt J, Le Souef P. Associations of the *IL12B* promoter polymorphism in longitudinal data from asthmatic patients 7 to 42 years of age. *J Allergy Clin Immunol* 2004;113:475–481. [PubMed: 15007350]
- Kurtzhals JA, Akanmori BD, Goka BQ, Adabayeri V, Nkrumah FK, Behr C, Hviid L. The cytokine balance in severe malarial anaemia. *J Infect Dis* 1999;180:1753–1755. [PubMed: 10515852]
- Kwiatkowski DP. How malaria has affected the human genome and what human genetics can teach us about malaria. *Am J Hum Genet* 2005;77:171–192. [PubMed: 16001361]
- Luty AJ, Lell B, Schmidt-Ott R, Lehman LG, Luckner D, Greve B, Matousek P, Herbich K, Schmid D, Migot-Nabias F, Deloron P, Nussenzweig RS, Kremsner PG. Interferon-gamma responses are associated with resistance to reinfection with *Plasmodium falciparum* in young African children. *J Infect Dis* 1999;179:980–988. [PubMed: 10068595]
- Luty AJ, Perkins DJ, Lell B, Schmidt-Ott R, Lehman LG, Luckner D, Greve B, Matousek P, Herbich K, Schmid D, Weinberg JB, Kremsner PG. Low interleukin-12 activity in severe *Plasmodium falciparum* malaria. *Infect Immun* 2000;68:3909–3915. [PubMed: 10858202]
- Luxemburger C, Ricci F, Nosten F, Raimond D, Bathet S, White NJ. The epidemiology of severe malaria in an area of low transmission in Thailand. *Trans R Soc Trop Med Hyg* 1997;91:256–262. [PubMed: 9231189]
- Ma X, Reich RA, Gonzalez O, Pan X, Fothergill AK, Starke JR, Teeter LD, Musser JM, Graviss EA. No evidence for association between the polymorphism in the 3' untranslated region of interleukin-12B and human susceptibility to tuberculosis. *J Infect Dis* 2003;188:1116–1118. [PubMed: 14551880]
- Marquet S, Doumbo O, Cabantous S, Poudiougou B, Argiro L, Safeukui I, Konate S, Sissoko S, Chevereau E, Traore A, Keita MM, Chevillard C, Abel L, Dessein AJ. A functional promoter variant in *IL12B* predisposes to cerebral malaria. *Hum Mol Genet* 2008;17:2190–2195. [PubMed: 18413324]
- McDevitt MA, Xie J, Gordeuk V, Bucala R. The anaemia of malaria infection: role of inflammatory cytokines. *Curr Hematol Rep* 2004;3:97–106. [PubMed: 14965485]
- Migot-Nabias F, Luty AJ, Ringwald P, Vaillant M, Dubois B, Renaut A, Mayombo RJ, Minh TN, Fievet N, Mbessi JR, Millet P, Deloron P. Immune responses against *Plasmodium falciparum* asexual blood-stage antigens and disease susceptibility in Gabonese and Cameroonian children. *Am J Trop Med Hyg* 1999;61:488–494. [PubMed: 10497996]
- Mitchell AJ, Hansen AM, Hee L, Ball HJ, Potter SM, Walker JC, Hunt NH. Early cytokine production is associated with protection from murine cerebral malaria. *Infect Immun* 2005;73:5645–5653. [PubMed: 16113282]
- Mohan K, Stevenson MM. Dyserythropoiesis and severe anaemia associated with malaria correlate with deficient interleukin-12 production. *Br J Haematol* 1998a;103:942–949. [PubMed: 9886304]
- Mohan K, Stevenson MM. Interleukin-12 corrects severe anaemia during blood-stage *Plasmodium chabaudi* AS in susceptible A/J mice. *Exp Hematol* 1998b;26:45–52. [PubMed: 9430513]
- Morahan G, Boutlis CS, Huang D, Pain A, Saunders JR, Hobbs MR, Granger DL, Weinberg JB, Peshu N, Mwaikambo ED, Marsh K, Roberts DJ, Anstey NM. A promoter polymorphism in the gene encoding interleukin-12 p40 (*IL12B*) is associated with mortality from cerebral malaria and with reduced nitric oxide production. *Genes Immun* 2002;3:414–418. [PubMed: 12424623]
- Mueller T, Mas-Marques A, Sarrazin C, Wiese M, Halangk J, Witt H, Ahlenstiel G, Spengler U, Goebel U, Wiedenmann B, Schreier E, Berg T. Influence of interleukin 12B (*IL12B*) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection. *J Hepatol* 2004;41:652–658. [PubMed: 15464247]
- Muller-Berghaus J, Kern K, Paschen A, Nguyen XD, Kluter H, Morahan G, Schadendorf D. Deficient IL-12p70 secretion by dendritic cells based on *IL12B* promoter genotype. *Genes Immun* 2004;5:431–434. [PubMed: 15175646]

- Nacher M, Treeprasertsuk S, Singhasivanon P, Silachamroon U, Vannaphan S, Gay F, Looareesuwan S, Wilairatana P. Association of hepatomegaly and jaundice with acute renal failure but not with cerebral malaria in severe falciparum malaria in Thailand. *Am J Trop Med Hyg* 2001;65:828–833. [PubMed: 11791981]
- Nair RP, Stuart P, Henseler T, Jenisch S, Chia NV, Westphal E, Schork NJ, Kim J, Lim HW, Christophers E, Voorhees JJ, Elder JT. Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C. *Am J Hum Genet* 2000;66:1833–1844. [PubMed: 10801386]
- Orozco G, Gonzalez-Gay MA, Paco L, Lopez-Nevo MA, Guzman M, Pascual-Salcedo D, Balsa A, Martin J. Interleukin 12 (*IL12B*) and interleukin 12 receptor (*IL12RB1*) gene polymorphisms in rheumatoid arthritis. *Hum Immunol* 2005;66:710–715. [PubMed: 15993716]
- Othoro C, Lal AA, Nahlen B, Koech D, Orago AS, Udhayakumar V. A low interleukin-10 tumor necrosis factor-alpha ratio is associated with malaria anaemia in children residing in a holoendemic malaria region in western Kenya. *J Infect Dis* 1999;179:279–282. [PubMed: 9841855]
- Peng JC, Abu Bakar S, Richardson MM, Jonsson JJ, Frazer IH, Nielsen LK, Morahan G, Thomas R. *IL10* and *IL12B* polymorphisms each influence IL-12p70 secretion by dendritic cells in response to LPS. *Immunol Cell Biol* 2006;84:227–232. [PubMed: 16519741]
- Perkins DJ, Weinberg JB, Kremsner PG. Reduced interleukin-12 and transforming growth factor-beta1 in severe childhood malaria: relationship of cytokine balance with disease severity. *J Infect Dis* 2000;182:988–992. [PubMed: 10950804]
- Prakash D, Fesel C, Jain R, Cazenave PA, Mishra GC, Pied S. Clusters of cytokines determine malaria severity in *Plasmodium falciparum*-infected patients from endemic areas of Central India. *J Infect Dis* 2006;194:198–207. [PubMed: 16779726]
- Rihet P, Traore Y, Aucan C, Traore-Leroux T, Kumulungui B, Traore AS, Abel L, Fumoux F. Genetic dissection of *Plasmodium falciparum* blood infection levels and other complex traits related to human malaria infection. *Parassitologia* 1999;41:83–87. [PubMed: 10697837]
- Robinson LJ, D'Ombrain MC, Stanistic DI, Taraika J, Bernard N, Richards JS, Beeson JG, Tavul L, Michon P, Mueller I, Schofield L. Cellular tumor necrosis factor, gamma interferon, and interleukin-6 responses as correlates of immunity and risk of clinical *Plasmodium falciparum* malaria in children from Papua New Guinea. *Infect Immun* 2009;77:3033–3043. [PubMed: 19380468]
- Sam H, Stevenson MM. Early IL-12 p70, but not p40, production by splenic macrophages correlates with host resistance to blood-stage *Plasmodium chabaudi* AS malaria. *Clin Exp Immunol* 1999;117:343–349. [PubMed: 10444268]
- Schmidt NW, Butler NS, Harty JT. CD8 T cell immunity to *Plasmodium* permits generation of protective antibodies after repeated sporozoite challenge. *Vaccine* 2009;27:6103–6106. [PubMed: 19712771]
- Schmieg J, Gonzalez-Aseguinolaza G, Tsuji M. The role of natural killer T cells and other T cell subsets against infection by the pre-erythrocytic stages of malaria parasites. *Microbes Infect* 2003;5:499–506. [PubMed: 12758279]
- Seegers D, Zwiers A, Strober W, Pena AS, Bouma G. A TaqI polymorphism in the 3'UTR of the IL-12 p40 gene correlates with increased IL-12 secretion. *Genes Immun* 2002;3:419–423. [PubMed: 12424624]
- Shear HL, Srinivasan R, Nolan T, Ng C. Role of IFN-gamma in lethal and nonlethal malaria in susceptible and resistant murine hosts. *J Immunol* 1989;143:2038–2044. [PubMed: 2506274]
- Shimokawa N, Nishiyama C, Hirota T, Tamari M, Hara M, Ikeda S, Okumura K, Ogawa H. Functional analysis of a polymorphism in the promoter region of the IL-12/23p40 gene. *Clin Exp Allergy* 2009;39:228–235. [PubMed: 19134014]
- Sieburth D, Jabs EW, Warrington JA, Li X, Lasota J, LaForgia S, Kelleher K, Huebner K, Wasmuth JJ, Wolf SF. Assignment of genes encoding a unique cytokine (IL12) composed of two unrelated subunits to chromosomes 3 and 5. *Genomics* 1992;14:59–62. [PubMed: 1358798]
- Socheat D, Denis MB, Fandeur T, Zhang Z, Yang H, Xu J, Zhou X, Phompida S, Phetsouvanh R, Lwin S, Lin K, Win T, Than SW, Htut Y, Prajakwong S, Rojanawatsirivet C, Tipmontree R, Vijaykadga S, Konchom S, Cong le D, Thien NT, Thuan le K, Ringwald P, Schapira A,

- Christophel E, Palmer K, Arbani PR, Prasittisuk C, Rastogi R, Monti F, Urbani C, Tsuyuoka R, Hoyer S, Otega L, Thimasarn K, Songcharoen S, Meert JP, Gay F, Crissman L, Cho Min N, Chansuda W, Darasri D, Indaratna K, Singhasivanon P, Chuprapawan S, Looareesuwan S, Supavej S, Kidson C, Baimai V, Yimsamran S, Buchachart K. Mekong malaria. II. Update of malaria, multi-drug resistance and economic development in the Mekong region of Southeast Asia. *Southeast Asian J Trop Med Public Health* 2003;34 Suppl 4:1–102. [PubMed: 15906747]
- Stephens R, Langhorne J. Priming of CD4+ T cells and development of CD4+ T cell memory; lessons for malaria. *Parasite Immunol* 2006;28:25–30. [PubMed: 16438673]
- Stevenson MM, Tam MF, Wolf SF, Sher A. IL-12-induced protection against blood-stage *Plasmodium chabaudi* AS requires IFN-gamma and TNF-alpha and occurs via a nitric oxide-dependent mechanism. *J Immunol* 1995;155:2545–2556. [PubMed: 7650384]
- Tangteerawatana P, Pichyangkul S, Hayano M, Kalambaheti T, Looareesuwan S, Troye-Blomberg M, Khusmith S. Relative levels of IL4 and IFN-gamma in complicated malaria: association with IL4 polymorphism and peripheral parasitaemia. *Acta Trop* 2007;101:258–265. [PubMed: 17379175]
- Tso HW, Lau YL, Tam CM, Wong HS, Chiang AK. Associations between *IL12B* polymorphisms and tuberculosis in the Hong Kong Chinese population. *J Infect Dis* 2004;190:913–919. [PubMed: 15295696]
- Verra F, Avellino P, Bancone G, Mangano V, Modiano D. Genetic epidemiology of susceptibility to malaria: not only academic exercises. *Parassitologia* 2008;50:147–150. [PubMed: 18693583]
- Verra F, Mangano VD, Modiano D. Genetics of susceptibility to *Plasmodium falciparum*: from classical malaria resistance genes towards genome-wide association studies. *Parasite Immunol* 2009;31:234–253. [PubMed: 19388945]
- Weatherall DJ. Genetic variation and susceptibility to infection: the red cell and malaria. *Br J Haematol* 2008;141:276–286. [PubMed: 18410566]
- WHO. Severe falciparum malaria; *Trans R Soc Trop Med Hyg.* 2000. p. 94
- Wroczynska A, Nahorski W, Bakowska A, Pietkiewicz H. Cytokines and clinical manifestations of malaria in adults with severe and uncomplicated disease. *Int Marit Health* 2005;56:103–114. [PubMed: 16532589]
- Yang JM, Nagasaka S, Yatagai T, Nakamura T, Kusaka I, Ishikawa SE, Saito T, Ishibashi S. Interleukin-12p40 gene (*IL-12B*) polymorphism and Type 1 diabetes mellitus in Japanese: possible role in subjects without having high-risk HLA haplotypes. *Diabetes Res Clin Pract* 2006;71:164–169. [PubMed: 16005098]
- Zwiers A, Seegers D, Heijmans R, Koch A, Hampe J, Nikolaus S, Pena AS, Schreiber S, Bouma G. Definition of polymorphisms and haplotypes in the interleukin-12B gene: association with IL-12 production but not with Crohn's disease. *Genes Immun* 2004;5:675–677. [PubMed: 15483662]



**Table 1**Demographic, parasitological, and clinical characteristics of patients with *P. falciparum* malaria.

Characteristic	Uncomplicated malaria	Severe malaria	<i>p</i>
Number, n	252	103	
Age, years	28.63 (0.63)	27.20 (1.13)	0.082 <sup>a</sup>
Gender, %F:%M	85:15	71:29	<b>0.002<sup>b</sup></b>
Parasitaemia, / $\mu$ L	27,511 (2,586)	286,302 (26,485)	< <b>0.001<sup>a</sup></b>
Haemoglobin, g/dL	12.12 (0.14)	11.56 (0.25)	0.091 <sup>a</sup>
RBC, $\times 10^6/\mu$ L	4.56(0.05)	4.28 (0.09)	<b>0.007<sup>a</sup></b>
WBC, $\times 10^3/\mu$ L	5.28 (0.17)	7.43 (0.51)	< <b>0.001<sup>a</sup></b>
Lymphocyte, $\times 10^3/\mu$ L	8.34 (0.43)	4.48 (0.48)	< <b>0.001<sup>a</sup></b>
Platelet, $\times 10^3/\mu$ L	98.12 (3.93)	50.56 (3.92)	< <b>0.001<sup>a</sup></b>
Total bilirubin, mg/dL	1.33(0.06)	6.36 (0.83)	< <b>0.001<sup>a</sup></b>
Creatinine, mg/dL	0.89 (0.02)	1.35 (0.12)	<b>0.029<sup>a</sup></b>

Data are the means (SEM, standard error of mean) unless otherwise noted.

<sup>a</sup>Statistical significance determined by pairwise comparisons with Student's t-test.

<sup>b</sup>Statistical significance determined by Chi-square analysis.

RBC, red blood cell; WBC, white blood cell.

Table 2

Levels of IL-12p40 and IFN- $\gamma$  in uncomplicated and severe malaria, and non-hyperparasitaemia vs. hyperparasitaemia.

	All Study Participants			Severe Malaria Patients		
	UM	SM	<i>P</i>	Non-hyperparasitaemia	Hyperparasitaemia	<i>P</i>
IL-12p40 (pg/mL), median (IQR)	27.0 (10.0–98.8)	95.1 (27.6–133.1)	<b>0.049</b>	35.1 (12.5–103.9)	121.9 (43.3–163.3)	<b>0.046</b>
sample size	56	25		14	11	
IFN- $\gamma$ (pg/mL), median (IQR)	283.5 (118.5–473.5)	387.0 (144.2–632.0)	<b>0.051</b>	333.0 (136.7–580.2)	486.0 (153.0–710.5)	0.228
sample size	106	75		42	33	

Patients with *P. falciparum* infection were categorized as uncomplicated or severe malaria according to WHO criteria (WHO, 2000). Patients with severe malaria were further stratified as non-hyperparasitaemia (<250,000 parasites/ $\mu$ L) and hyperparasitaemia ( $\geq$ 250,000 parasites/ $\mu$ L). IL-12p40 and IFN- $\gamma$  were measured in those subjects with adequate volumes of available plasma samples. Results are presented as median and interquartile range (IQR), with  $p \leq 0.05$  considered statistically significant. Mann-Whitney U test was used to compare cytokine levels between the disease conditions.

**Table 3**Distribution of *IL12B* genotypes in patients with uncomplicated and severe malaria.

	Genotype frequency			<i>P</i> ( <i>X</i> )
	1.1, <i>n</i> (%)	1.2, <i>n</i> (%)	2.2, <i>n</i> (%)	
<b><i>IL12B</i>pro (rs17860508)</b>				
UM	17 (6.8)	185 (74.0)	48 (19.2)	<i>P</i> (2.2)=0.56
SM	14 (13.6)	72 (69.9)	17 (16.5)	<i>P</i> (2.2)=0.51
Total	31 (8.8)	257 (72.8)	65 (18.4)	<i>P</i> (2.2)=0.55
<i>p</i> (UM vs. SM)	<b><i>p</i>=0.017</b>	<i>p</i> =0.288	<i>p</i> =0.224	
<b><i>IL12B</i> 3' UTR (rs3212227)</b>	<b>TT, <i>n</i> (%)</b>	<b>TG, <i>n</i> (%)</b>	<b>GG, <i>n</i> (%)</b>	
UM	61 (27.1)	104 (46.2)	60 (26.7)	<i>P</i> ( <i>G</i> )=0.50
SM	20 (23.8)	34 (40.5)	30 (35.7)	<i>P</i> ( <i>G</i> )=0.56
Total	81 (26.2)	138 (44.7)	90 (29.1)	<i>P</i> ( <i>G</i> )=0.51
<i>p</i> (UM vs. SM)	<i>p</i> =0.259	<i>p</i> =0.128	<b><i>p</i> =0.021</b>	

Data are presented as proportions, *n* (%).

UM, uncomplicated malaria (*n*=252); SM, severe malaria (*n*=103).

*P*(*X*), frequency of the wild allele in the population.

*IL12B*pro did not amplify in *one* subject with UM and *one* subject with SM, while *IL12B* 3' UTR did not amplify in 37 subjects with UM and 9 subjects with SM.

Statistical significance for differences in genotypic frequencies between the UM and SM groups was determined by Chi-square analysis.

Table 4

Association between *IL12B* polymorphisms and severe disease outcomes.

Genotype	Severe malaria		Hyperparasitaemia ( $\geq 250,000/\mu\text{L}$ )	
	Odds ratio	95% CI	Odds ratio	95% CI
<b><i>IL12B</i>pro (rs17860508)</b>				
2.2 (n=65)	reference		reference	
1.2 (n=257)	1.04	0.55–1.94	0.77	0.33–1.80
1.1 (n=31)	2.34	0.94–5.81	3.42	1.17–9.97
				<b>0.025</b>
<b><i>IL12B</i> 3' UTR (T/G)(rs3212227)</b>				
TT (n=90)	reference		reference	
TG (n=138)	0.61	0.33–1.00	0.80	0.35–1.79
GG (n=81)	0.70	0.36–1.39	0.99	0.40–2.46

Patients with *P. falciparum* infection were categorized according to WHO criteria (WHO, 2000) for severe malaria. Patients with severe malaria were also categorized as hyperparasitaemia ( $\geq 250,000$  parasites/ $\mu\text{L}$ ) vs. non-hyperparasitaemia ( $< 250,000$  parasites/ $\mu\text{L}$ ). Multivariate logistic regression analyses were performed, controlling for the confounding effects of age and gender. Results are presented as odds ratio (OR) and 95% confidence interval (CI), with  $p \leq 0.05$  considered statistically significant.

Table 5

Haplotypic association between *IL12B* polymorphisms and severe disease outcomes.

Haplotype	Severe malaria			Hyperparasitaemia ( $\geq 250,000/\mu\text{L}$ )		
	Odds ratio	95% CI	<i>p</i> -value	Odds ratio	95% CI	<i>p</i> -value
<i>IL12B</i> pro-2/3' UTR-T	0.51	0.29-0.90	0.020	0.57	0.28-1.18	0.132
<i>IL12B</i> pro-2/3' UTR-G	1.49	0.83-2.69	0.181	0.90	0.40-2.03	0.795
<i>IL12B</i> pro-1/3' UTR-T	1.52	0.70-3.30	0.292	2.15	0.84-5.53	0.112
<i>IL12B</i> pro-1/3' UTR-G	0.87	0.49-1.57	0.645	0.76	0.35-1.64	0.487

Patients with *P. falciparum* infection were categorized according to WHO criteria (WHO, 2000) for severe malaria and stratified based on their *IL12B* haplotypes (*IL12B*pro/3' UTR). Patients were also categorized as non-hyperparasitaemia ( $< 250,000$  parasites/ $\mu\text{L}$ ) and hyperparasitaemia ( $\geq 250,000$  parasites/ $\mu\text{L}$ ). Multivariate logistic regression analyses were performed, controlling for the confounding effects of age and gender. Results are presented as odds ratio (OR) and 95% confidence interval (CI), with  $p \leq 0.05$  considered statistically significant for those with versus those without the haplotype.



**Table 6**  
Functional relationship between *IL12B* genotypes/haplotypes and IL-12p40 and IFN- $\gamma$ .

	Uncomplicated Malaria					Severe Malaria				
	1.1	1.2	2.2	<i>p</i>		1.1	1.2	2.2	<i>p</i>	
<b><i>IL12B</i>pro (rs17860508)</b>										
IL-12p40 (pg/mL), median (IQR)	10.0 (10.0–10.0)	75.4 (13.5–112.5)	20.0 (10.0–69.3)	<b>0.002</b>	37.6 (16.8–229.8)	99.2 (27.1–135.0)	95.1 (35.9–131.4)		0.919	
sample size	7	30	19		4	16	5			
IFN- $\gamma$ (pg/ mL), median (IQR)	438.5*(227.7–585.2)	338.5 (125.5–522.2)	140.0 (43.0–314.0)	<b>0.004</b>	550.5 (204.5–692.7)	340.5 (164.7–629.7)	242.0 (105.0–677.0)		0.508	
sample size	10	94	19		12	62	15			
<b><i>IL12B</i> 3' UTR (rs3212227)</b>										
TT										
TG										
GG										
TT										
TG										
GG										
IL-12p40 (pg/mL), median (IQR)	22.1 (10.0–87.8)	41.1 (10.0–104.8)	26.7 (10.0–108.3)	0.622	95.1 (26.6–131.4)	65.6 (21.0–143.5)	76.7 (27.0–148.0)		0.892	
sample size	20	28	13		9	6	10			
IFN- $\gamma$ (pg/ mL), median (IQR)	160.0 (88.0–413.0)	329.0 (125.0–450.0)	374.5 (230.5–593.0)	0.083	382.5 (113.5–623.2)	265.0 (170.5–633.0)	432.5 (162.5–623.5)		0.921	
sample size	23	55	26		16	29	28			
<b>Haplotypes</b>										
<i>IL12B</i> pro-2/3' UTR-T										
<i>IL12B</i> pro-2/3' UTR-G										
<i>IL12B</i> pro-1/3' UTR-T										
<i>IL12B</i> pro-1/3' UTR-G										
0	1	0	1		0	1	0	1		
IL-12p40 (pg/mL), median (IQR)	32.2 (10.0–112.9)	49.8 (10.2–103.5)	38.1 (10.0–102.5)	74.3 (15.6–118.6)	39.9 (12.8–108.0)	10.0 (10.0–92.4)	27.1 (10.0–95.1)	39.9 (11.8–116.9)		
sample size	27	54	62	19	70	11	33	48		
<i>p</i> -value		0.596	0.354		0.263		0.219			

	Uncomplicated Malaria			Severe Malaria			<i>p</i>	
	1.1	1.2	<i>p</i>	1.1	1.2	2.2		
<b><i>IL12Bpro</i> (rs17860508)</b>								
IFN- $\gamma$ (pg/ mL), median (IQR)	387.0 (164.0–597.0)	267.5 (117.5–527.0)	321.5 (128.0–542.0)	338.0 (130.0–495.0)	314.0 (125.0–517.0)	406.5 (160.5–619.5)	199.0 (108.5–537.5)	343.5 (159.0–541.0)
sample size	65	116	128	53	157	24	51	130
<i>p</i> -value		<b>0.06</b>	0.953	0.252				0.158

Patients with *P. falciparum* infection were categorized according to severe malaria according to WHO criteria (WHO, 2000). Patients were categorized as hyperparasitaemia ( $\geq 250,000$  parasites/ $\mu$ L) vs. non-hyperparasitaemia ( $< 250,000$  parasites/ $\mu$ L). IL-12p40 and IFN- $\gamma$  were measured in those subjects with adequate volumes of available plasma samples. Across group comparisons were determined by Kruskal-Wallis test, while pairwise comparisons was by Mann-Whitney U test. Results are presented as median and interquartile range (IQR), with  $p \leq 0.05$  considered statistically significant. For the haplotypic constructions, results are presented as those without (code=0) versus those with (code=1) the particular haplotypes.